On February 2, 2022, H. Jeffrey Wilkins resigned as Chief Medical Officer of Avalo Therapeutics, Inc., to be effective upon a date to be agreed upon. Dr. Wilkins will assist in an orderly transition of his duties through the effective date of his resignation.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
12.6 USD | -4.14% |
|
+2.81% | +38.52% |
Jun. 24 | Avalo Therapeutics Names Chief Legal Officer | MT |
Jun. 24 | Avalo Therapeutics, Inc. Appoints Paul Varki as Chief Legal Officer | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.52% | 13.6M | |
+17.84% | 44.63B | |
+43.57% | 40.46B | |
-8.92% | 38.07B | |
+33.42% | 32.27B | |
-8.98% | 27.3B | |
+14.49% | 26.53B | |
+45.75% | 14.06B | |
+32.54% | 12.54B | |
-8.64% | 11.28B |
- Stock Market
- Equities
- AVTX Stock
- News Avalo Therapeutics, Inc.
- Avalo Therapeutics, Inc. Announces Resignation of H. Jeffrey Wilkins as Chief Medical Officer